Results 201 to 210 of about 99,040 (285)

High‐Altitude Adaptation of Frogs (Case Study: Nanorana parkeri): From Physiological Phenotypes to AltitudeOmics

Integrative Zoology, EarlyView.
High altitudes are challenging for the animals that inhabit these environments. The Xizang plateau frog (Nanorana parkeri) survives in high‐altitude environments through a synergistic strategy of metabolic remodeling and protein expression adjustment to optimize energy efficiency and enhance cellular protection.
Xuejing Zhang, Yonggang Niu, Shengkang Men, Yanghuilin Zhang, Xiaolong Tang, Kenneth B. Storey, Qiang Chen   +6 more
wiley   +1 more source

Hepatic Peliosis due to Azathioprine in a Pediatric Kidney Transplant Recipient. [PDF]

Case Reports Hepatol
Mouche A, Parmentier C, Almes M, Mussini C, Ulinski T, Delbet JD.   +5 more
europepmc   +1 more source

Postbiotics and Nicotinamide Utilize Distinct Mechanisms to Improve Skin Barrier Integrity, Inflammation, and Keratinocyte Differentiation

Allergy, EarlyView.
Integrating skin barrier measurements with omics and machine learning, we found that postbiotics and NAM regulate skin homeostasis through distinct, strain‐ and dose‐dependent mechanisms. Postbiotics primarily modulate skin barrier function by promoting keratinocyte differentiation and suppressing inflammation.
Yagiz Pat, Duygu Yazici, Huseyn Babayev, Sena Ardicli, Xiangting Bu, Sheri Simmons, Anthony Almada, Christine Avena, Tye Jensen, Raja Dhir, Patrick Westermann, Asuncion Garcia‐Sanchez, Manru Li, Ozge Ardicli, Can Zeyneloglu, Marco Pane, Angela Amoruso, Christoph Messner, Ismail Ogulur, Yasutaka Mitamura, Mubeccel Akdis, Cezmi A. Akdis   +21 more
wiley   +1 more source

Amino acids, purines, and pyrimidines as potential biochemical markers of bipolar disorder - current state of knowledge. [PDF]

Postep Psychiatr Neurol
Sadko KG, Wichowicz H.
europepmc   +1 more source

Antirhinovirus activity of purine nucleoside analogs

, 1986
Erik De Clercq, R Bernaerts, D. E. BERGSTROM, M. J. ROBINS, John A. Montgomery, Antonı́n Holý   +5 more
openalex   +2 more sources

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source

The Bidirectional Mechanism of Uric Acid Levels on Alzheimer's Disease: A Narrative Review. [PDF]

Int J Gen Med
Zhao J, Wang X, Li B.
europepmc   +1 more source

Studies of Nucleosides and Nucleotides. XXXII. Purine Cyclonucleosides. 3. Synthesis of 2'-Deoxy- and 3'-Deoxyadenosine from Adenosine

, 1967
Morio Ikehara, Hiroshi Tada
openalex   +2 more sources

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Mechanistic Insights into the Stabilizing Role of Deep Eutectic Solvents for Nucleic Acids: An <i>In Silico</i> Analysis. [PDF]

J Phys Chem B
Hardy DE, Albert A, Lipani J, Metott ZJ, Mirjafari A, Wagle DV.   +5 more
europepmc   +1 more source